REPORT FROM THE 25TH CONGRESS OF THE EUROPEAN COMMITTEE FOR TREATMENT AND RESEARCH IN MULTIPLE SCLEROSIS (ECTRIMS) – AMSTERDAM, THE NETHERLANDS, OCTOBER 19-22, 2011 – MS patients receiving a disease-modifying therapy (DMT) typically stop treatment or switch medications within a few years of starting treatment, according to a new database analysis of MS patients in British Columbia, Canada (Evans et al. ECTRIMS 2011; abstract P687).
Latest News
Complexities in targeting B cells in MS
October 21, 2011REPORT FROM THE 25TH CONGRESS OF THE EUROPEAN COMMITTEE FOR TREATMENT AND RESEARCH IN MULTIPLE SCLEROSIS (ECTRIMS) – AMSTERDAM, THE NETHERLANDS, OCTOBER 19-22, 2011 – Two studies targeting B cells report mixed results – one positive, the other negative – in the treatment of MS, suggesting that there may be hidden challenges for this novel therapeutic approach.
BG-12 in RRMS: DEFINE trial results
October 21, 2011REPORT FROM THE 25TH CONGRESS OF THE EUROPEAN COMMITTEE FOR TREATMENT AND RESEARCH IN MULTIPLE SCLEROSIS (ECTRIMS) – AMSTERDAM, THE NETHERLANDS, OCTOBER 19-22, 2011 – The experimental oral therapy BG-12 (dimethyl fumarate) appears to be effective in reducing relapses and disability progression, according to the results of the phase III DEFINE study (Gold et al. ECTRIMS 2011; abstract 95).
Worsening MS patients turn to the Internet
October 20, 2011REPORT FROM THE 25TH CONGRESS OF THE EUROPEAN COMMITTEE FOR TREATMENT AND RESEARCH IN MULTIPLE SCLEROSIS (ECTRIMS) – AMSTERDAM, THE NETHERLANDS, OCTOBER 19-22, 2011 – An Internet survey of MS patients reports that as patients worsen, they are increasingly likely to turn to the Internet rather than their neurologist for MS information (Miller et al. ECTRIMS 2011; abstract P178).